Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference

---

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

---

NEW YORK, NY, March 04, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 2021.

The Company’s presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021. A replay of the presentation will be available on the “News & Events” section of the Enzo Biochem website following the conference.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Forward-Looking Statements

Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

###

Contact:

For Enzo Biochem, Inc.

David Bench, CFO 212-583-0100dbench@enzo.com

Media:

Marisa MonteBerry & Company Public Relations212-253-8881mmonte@berrypr.com

Investors:

Jeremy FefferLifeSci Advisors, LLC212-915-2568jeremy@lifesciadvisors.com

Steve AnrederAnreder & Company212-532-3232Steven.anreder@anreder.com

Source: Enzo Biochem, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AGC Biologics Expands Partnership with Rocket Pharmaceuticals
• Looking For Top Marijuana Stocks On 420? 2 Pot Stocks For Your Watchlist
• Thought Industries Customer Education Platform Enables SonoSim to Advance Medical Education